FDA advisory panel recommends Savient’s gout drug – Krystexxa - for approval
Submitted by Jason Ramsey on Wed, 06/17/2009 - 14:33
In a 14-1 vote, a US advisory panel of arthritis experts Tuesday recommended Savient Pharmaceuticals Inc's experimental gout drug - Krystexxa - for approval by the Food and Drug Administration.
The FDA's final decision on Savient's Krystexxa drug is likely to come by the end of July.
Review Time for Experimental Gout Drug Extended by FDA
Submitted by Jason Ramsey on Fri, 02/13/2009 - 16:21
Savient Pharmaceuticals Inc. in a statement said the U. S. food and Drug Administration has extended the review date for the company's experimental gout drug by three months. The news sent the company's shares plummeting down 29 % to $2.05 in afterhours trading.
Latest News
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
